Company Overview
Development of Focal Adhesion Kinase (FAK) inhibiting drug candidates AMP886 and AMP945.
Website | www.ampliatx.com |
---|---|
Head Office | Melbourne VIC |
Registry | Computershare Investor Services |
CEO | John Lambert, Christopher Burns |
Chair Person | Warwick Tong |
GICS Industry | Pharmaceuticals, Biotechnology & Life Sciences |
Sub Industry | Biotechnology |
Sector | Health Care |
Market Cap | $17 m |
---|---|
Shares on Issue | 194 m |
Status | Trading |
Last Price | |
Change | |
52 Week H/L | |
VWAP | |
Bid/Ask |
Directors and Management
Mr Andrew John Cooke
Company Secretary 11/10/2013
Mr Cooke has experience in law, corporate finance, governance and compliance. As a Non-Executive Director and Company Secretary of a number of ASX listed companies he has over 25 years of boardroom experience and has developed a practical blend of legal and commercial acumen. He has served as a consultant to listed, public and private companies in the resources, property and biotech sectors focussing on stock exchange and regulatory compliance and a wide range of corporate transactions. Andrew has been the Company Secretary since 11 October 2013.
LLB, MAICD, FAICS Male
Dr John Lambert
Chief Executive Officer,Managing Director 24/06/2019
Dr Lambert has more than 18 years of drug discovery and development experience. His prior appointments included leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), primarily working on the development of respiratory antiviral drugs. As a Senior Director at Medicines Development for Global Health, John was a member of the team that received approval in 2018 from the US FDA for moxidectin as a treatment for river blindness. Prior to working in industry John was an academic researcher in organic, medicinal and biological chemistry (University of Melbourne, ANU and Harvard University). John is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the entire spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.
Post-doctural studies(Laboratories & ANU), B.Sc. ( Chemist Male
Dr Robert Peach
Non-Executive Director 02/09/2015
Dr Peach has 30 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry. In 2009 he co-founded Receptos Limited, becoming Chief Scientific Officer and raising US$59M in venture capital and US$800M in an IPO and three subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for US$7.8B. Robert held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments. His drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs. He is currently on the Board of Directors of AdAlta Pty Limited and Rekover Therapeutics, and serves on the Scientific Advisory Board of Eclipse Bioinnovations. Robert is the co-author of 70 scientific publications and book chapters, and 26 patents and patent applications.
BSc, MSc, PhD Male
Ms S Jane Catherine Bell
Non-Executive Director 12/04/2021
Ms Bell is a non-executive director with more than 30 years' experience in law firms, financial services and corporate treasury operations gained living in Melbourne, London, Toronto, San Francisco and Brisbane. Jane has been a non-executive director since 2002, serving on 12 boards including nine health and medical research boards. Jane currently serves as Deputy Chair of Monash Health, Director of Jessie McPherson Private Hospital, Chair of the Community Advisory Group of the Melbourne Genomics Health Alliance and is a Member of the Administrative Appeals Tribunal. Jane is a former Chair of Melbourne Health (Royal Melbourne Hospital), Chair of Biomedical Research Vic, Deputy Chair of Westernport Water Corporation, Director of UCA Funds Management, WorkSafe Victoria, Hudson Institute of Medical Research-Monash Institute of Medical Research-Prince Henry's Institute of Medical Research, Queensland Institute of Medical Research Trust, Australian Red Cross (Qld) and Victorian Women's Housing Association.
BEco, LLB, LLM, FAICD Lawyer Female
Dr Warwick Bonner Tong
Non-Executive Director,Non-Executive Chairman 04/05/2018
Dr Tong is a NZ trained physician with more than 25 years experience in the Pharmaceutical and Biotechnology industry. After his early career in General Medical Practice Warwick has held a wide variety of roles in the pharmaceutical and biotech industry in NZ(Glaxo) Singapore (GlaxoWellcome) London (GSK), Boston (Surface Logix) and Melbourne (CTx - Cancer Therapeutics CRC). Warwick currently serves as director of Aculeus Therapeutics Pty Ltd, CannaPacific Pty Ltd and its affiliate e3D Pharma Pty Ltd. He is a member of the Strategic Advisory Board of the Maurice Wilkins Centre in Auckland NZ and of the CSIRO Manufacturing Business Advisory Committee. Warwick is a former CEO and director of CTx, director and Chair of the CTx commercialisation company, CTxONE, and director and Chair of BioMedVic.
MB, ChB, MPP, GAICD, Senior Scholar Medicine Physician Male
Dr Christopher John Burns
Non-Executive Director 04/05/2018
Dr Burns is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for 25 years. After completing a PhD in Organic Chemistry at the University of Melbourne Chris undertook post-doctoral studies in the USA before moving to Pfizer UK, where he worked on a variety of drug discovery projects. After 5 years he returned to Australia as a Research Fellow at the University of Sydney with the CRC for Molecular Engineering and Technology and after two years moved to the biotechnology company Ambri as Head of Chemistry. Chris then moved to the Melbourne-based biotech as Head of Medicinal Chemistry and later as Research Director. During this time he led teams in the discovery of two anti-cancer agents that have entered clinical trial, including the drug momelotinib which successfully completed Phase III studies. Most recently Chris was a Laboratory Head at the Walter and Eliza Hall Institute of Medical Research in Melbourne and currently holds executive roles with privately held biotechs MecRx, Certa Therapeutics and OccuRx. Dr Burns is the inventor on over 30 patents and a co-author on over 50 scientific publications.
BSc(Hons), PhD(Organic Chem) , FRACI, FRSC Male
Top 20 Shareholders
Name | Shares | % | |
---|---|---|---|
1. | HSBC Custody Nominees (Australia) Limited | 20,374,618 | 16.32 |
2. | Bond Street Custodians Limited <Lam1 D08047 A/C> | 8,750,000 | 7.01 |
3. | Citicorp Nominees Pty Limited | 5,803,803 | 4.65 |
4. | BNP Paribas Noms Pty Ltd <Drp> | 4,595,985 | 3.68 |
5. | Ctxt Pty Ltd | 4,514,468 | 3.62 |
6. | Elk River Holdings Pty Ltd | 2,942,142 | 2.36 |
7. | Christopher John Burns | 2,472,243 | 1.98 |
8. | Warwick Tong | 2,355,140 | 1.89 |
9. | 34Th Avenue Pty Ltd <Devlin Family A/C> | 2,215,237 | 1.77 |
10. | Gp Securities Pty Ltd | 1,930,000 | 1.55 |
11. | Mr Andrew Podolak | 1,925,000 | 1.54 |
12. | Mark Sullivan <Aems Consulting A/C> | 1,661,428 | 1.33 |
13. | Cancer Research Technology Limited | 1,360,524 | 1.09 |
14. | HWH Power Pty Ltd <Hwh Super Fund A/C> | 1,270,000 | 1.02 |
15. | Merrill Lynch (Australia) Nominees Pty Limited | 1,058,057 | 0.85 |
16. | Cofactor Llc | 1,000,000 | 0.80 |
17. | Swanmark Super Pty Ltd <Rc Swan Super Fund A/C> | 1,000,000 | 0.80 |
18. | Ravinna Pty Ltd <Ravinna A/C> | 993,992 | 0.80 |
19. | Mr Michael Andrew Whiting and Mrs Tracey Anne Whiting <Whiting Family S/F A/C> | 940,000 | 0.75 |
20. | Margaret Frame | 923,016 | 0.74 |
Director Transactions
Date | Name | Qty | Value | Direction | Notes |
---|---|---|---|---|---|
02/09/2021 | S Jane Bell | 557,646 | $115,432 | Buy | On-market trade. |
01/09/2021 | S Jane Bell | 36,268 | $6,890 | Buy | On-market trade. |
07/06/2021 | John Lambert | 130,000 | $20,150 | Issued | Exercise of options. |
07/06/2021 | John Lambert | 130,000 | $20,150 | Exercise | Exercise of options. As per announcement on 08/06/2021. |